Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 3 (1)

Trial Status

Terminated1
Recruiting1
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT00565851Phase 3Active Not Recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT06612827RecruitingPrimary

Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

NCT00570674Phase 1Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Showing all 3 trials

Research Network

Activity Timeline